{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T10:26:41Z","timestamp":1770546401302,"version":"3.49.0"},"reference-count":29,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kelly Day Foundation","award":["RFE1"],"award-info":[{"award-number":["RFE1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Epithelial adenocarcinoma of the ovary and colon are associated with the highest rates of cancer-related deaths in women in the U.S. The literature supports the role of HDL-associated apolipoproteins in the treatment of cancer and other pro-inflammatory diseases. Previously, we developed a novel 20-amino acid mimetic peptide, HM-10\/10, which potently inhibits tumor development and growth in colon and ovarian cancer. Here, we report the properties of HM-10\/10 relative to its stability in vitro. The results demonstrated that HM-10\/10 had the highest half-life in human plasma compared to plasma from other species tested. HM-10\/10 demonstrated stability in human plasma and simulated gastric environment, increasing its promise as an oral pharmaceutical. However, under conditions modeling the small intestine, HM-10\/10 demonstrated significant degradation, likely due to the peptidases encountered therein. Furthermore, HM-10\/10 demonstrated no evidence of time-dependent drug\u2013drug interactions, although it demonstrated CYP450 induction slightly above cutoff. As proteolytic degradation is a common limitation of peptide-based therapeutics, we are pursuing strategies to improve the stability properties of HM-10\/10 by extending its bioavailability while retaining its low toxicity profile. HM-10\/10 holds promise as a new agent to address the international women\u2019s health crisis of epithelial carcinomas of the ovary and colon.<\/jats:p>","DOI":"10.3390\/ijms241210054","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T02:00:45Z","timestamp":1686621645000},"page":"10054","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Stability Characterization of the Novel Anti-Cancer HM-10\/10 HDL-Mimetic Peptide"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3644-8275","authenticated-orcid":false,"given":"Michael P.","family":"Dempsey","sequence":"first","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"},{"name":"David Geffen School of Medicine, The University of California at Los Angeles, Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelyn E.","family":"Andersen","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"},{"name":"David Geffen School of Medicine, The University of California at Los Angeles, Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8516-3032","authenticated-orcid":false,"given":"Brittney M.","family":"Wells","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0062-094X","authenticated-orcid":false,"given":"Mitchell A.","family":"Taylor","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clay L.","family":"Cashman","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4237-476X","authenticated-orcid":false,"given":"Lesley B.","family":"Conrad","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"},{"name":"David Geffen School of Medicine, The University of California at Los Angeles, Los Angeles, CA 90095, USA"},{"name":"Lynch Comprehensive Cancer Research Center, School of Medicine, Creighton University, Omaha, NE 68178, USA"},{"name":"Office of the President, Western University of Health Sciences, Pomona, CA 91766, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2531-9513","authenticated-orcid":false,"given":"Claire A.","family":"Kearney","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary B.","family":"Conklin","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily R.","family":"Via","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily M.","family":"Doe","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravikiran","family":"Komirisetty","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, David Geffen School of Medicine, The University of California at Los Angeles, Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Dearborn","sequence":"additional","affiliation":[{"name":"Charles River Laboratories International, Stone Ridge, NY 12484, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2959-9531","authenticated-orcid":false,"given":"Srinivasa T.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, David Geffen School of Medicine, The University of California at Los Angeles, Los Angeles, CA 90095, USA"},{"name":"Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, The University of California at Los Angeles, Los Angeles, CA 90095, USA"},{"name":"Jonsson Comprehensive Cancer Center, The University of California at Los Angeles, Los Angeles, CA 90095, USA"},{"name":"Interdepartmental Program in Molecular Toxicology, School of Public Health, University of California at Los Angeles, Los Angeles, CA 90095, USA"},{"name":"California NanoSystems Institute, University of California at Los Angeles, Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Farias-Eisner","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Omaha, NE 68178, USA"},{"name":"David Geffen School of Medicine, The University of California at Los Angeles, Los Angeles, CA 90095, USA"},{"name":"Lynch Comprehensive Cancer Research Center, School of Medicine, Creighton University, Omaha, NE 68178, USA"},{"name":"Office of the President, Western University of Health Sciences, Pomona, CA 91766, USA"},{"name":"Office of the President, Western University of Health Sciences, Lebanon, OR 97355, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3322\/caac.21559","article-title":"Epithelial ovarian cancer: Evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer. J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1158\/1078-0432.CCR-12-2243","article-title":"New strategies in the treatment of ovarian cancer: Current clinical perspectives and future potential","volume":"19","author":"Banerjee","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3389\/fphar.2018.01524","article-title":"Anti-tumorigenic and platinum-sensitizing effects of apolipoprotein A1 and apolipoprotein A1 mimetic peptides in ovarian cancer","volume":"9","author":"Marinho","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1194\/jlr.R051367","article-title":"Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: A review","volume":"55","author":"White","year":"2014","journal-title":"J. Lipid Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/ATVBAHA.112.300282","article-title":"High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: Novel hypotheses and review of literature. Arterioscler","volume":"32","author":"Navab","year":"2012","journal-title":"Thromb. Vasc. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/biof.1205","article-title":"The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory","volume":"41","author":"Gao","year":"2015","journal-title":"Biofactors"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"19997","DOI":"10.1073\/pnas.1009010107","article-title":"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer","volume":"107","author":"Su","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","first-page":"101","article-title":"Bovine HDL and Dual Domain HDL-Mimetic Peptides Inhibit Tumor Development in Mice","volume":"8","author":"Su","year":"2020","journal-title":"J. Cancer Res. Ther. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Su, F., Spee, C., Araujo, E., Barron, E., Wang, M., Ghione, C., Hinton, D.R., Nusinowitz, S., Kannan, R., and Reddy, S.T. (2019). A Novel HDL-Mimetic Peptide HM-10\/10 Protects RPE and Photoreceptors in Murine Models of Retinal Degeneration. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194807"},{"key":"ref_13","unstructured":"Ali, R., Rani, R., and Kumar, S. (2013). Advances in Protein Chemistry, OMICS Group eBooks."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.2174\/092986712801661004","article-title":"The use of therapeutic peptides to target and to kill cancer cells","volume":"19","author":"Boohaker","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.coph.2008.06.002","article-title":"Discovering and improving novel peptide therapeutics","volume":"8","author":"McGregor","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/bph.13608","article-title":"Potential role of bioactive peptides in prevention and treatment of chronic diseases: A narrative review","volume":"174","author":"Cicero","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"967347","DOI":"10.1155\/2012\/967347","article-title":"Cancer treatment using peptides: Current therapies and future prospects","volume":"2012","author":"Thundimadathil","year":"2012","journal-title":"J. Amino Acids."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12929-017-0328-x","article-title":"Evaluation of the use of therapeutic peptides for cancer treatment","volume":"24","author":"Marqus","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The future of peptide-based drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1021\/acs.jmedchem.7b00969","article-title":"Relevance of Half-Life in Drug Design","volume":"61","author":"Smith","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/rcm.3467","article-title":"Specificity of immobilized porcine pepsin in H\/D exchange compatible conditions","volume":"22","author":"Hamuro","year":"2008","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.4155\/tde.13.104","article-title":"Basics and recent advances in peptide and protein drug delivery","volume":"4","author":"Bruno","year":"2013","journal-title":"Ther. Deliv."},{"key":"ref_23","unstructured":"Herman, T.F., and Santos, C. (2021). StatPearls, StatPearls Publishing LLC."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1007\/s11095-012-0724-6","article-title":"Drug-drug interaction potential of marketed oncology drugs: In vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction","volume":"29","author":"Kenny","year":"2012","journal-title":"Pharm. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/dmd.120.000055","article-title":"Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Guidelines on Model Fitting and Recommendations on Time Course for In Vitro Cytochrome P450 Induction Studies Including Impact on Drug Interaction Risk Assessment","volume":"49","author":"Wong","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","article-title":"Inhibition and induction of CYP enzymes in humans: An update","volume":"94","author":"Hakkola","year":"2020","journal-title":"Arch. Toxicol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/clpt.2011.75","article-title":"Biomarkers in solid organ transplantation","volume":"90","author":"Gieser","year":"2011","journal-title":"Clin Pharmacol Ther."},{"key":"ref_28","first-page":"30","article-title":"Pharmacokinetic and Pharmacodynamic Considerations for Drugs Binding to Alpha-1-Acid Glycoprotein","volume":"36","author":"Smith","year":"2018","journal-title":"Pharm. Res. Pharm Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"11481","DOI":"10.1021\/acsomega.9b01272","article-title":"Sustained Release of Vascular Endothelial Growth Factor from Poly(\u03b5-caprolactone-PEG-\u03b5-caprolactone)-b-Poly(l-lactide) Multiblock Copolymer Microspheres","volume":"4","author":"Scheiner","year":"2019","journal-title":"ACS Omega"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/10054\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:53:45Z","timestamp":1760126025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/10054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ijms241210054"],"URL":"https:\/\/doi.org\/10.3390\/ijms241210054","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]}}}